activating mutations alk provide therapeutic target neuroblastoma
neuroblastoma embryonal tumour peripheral sympathetic nervous system accounts approximately % deaths due childhood cancer high risk neuroblastomas rapidly progressive even intensive myeloablative chemotherapy relapse common almost uniformly fatal report detection previously unknown mutations alk gene encodes receptor tyrosine kinase % primary neuroblastomas five non synonymous sequence variations identified kinase domain alk three somatic two germ line frequent mutation f1174l also identified three different neuroblastoma cell lines alk complementary dnas encoding f1174l r1275q variants wild type alk cdna transformed interleukin--dependent murine haematopoietic ba/f3 cells cytokine-independent growth ba/f3 cells expressing mutations sensitive small molecule inhibitor alk tae684 ref furthermore two human neuroblastoma cell lines harbouring f1174l mutation also sensitive inhibitor cytotoxicity associated increased amounts apoptosis measured tdt-mediated dutp nick end labelling tunel short hairpin rna shrna mediated knockdown alk expression neuroblastoma cell lines f1174l mutation also resulted apoptosis impaired cell proliferation thus activating alleles alk receptor tyrosine kinase present primary neuroblastoma tumours established neuroblastoma cell lines confer sensitivity alk inhibition small molecules providing molecular rationale targeted therapy disease
